Global Cardiopulmonary Exercise Test Market Size was USD 0.34 Billion in 2025, this report covers Market growth, trend, opportunity and forecast from 2026-2032

The Cardiopulmonary Exercise Test market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.

1. Vyaire Medical Inc.:

   Vyaire Medical Inc. holds a prominent position in the global Cardiopulmonary Exercise Test ecosystem, particularly through its specialized respiratory diagnostics and CPET systems used in pulmonary function laboratories, cardiology departments, and sports medicine centers. The company leverages its broad installed base in pulmonary diagnostics to cross-sell CPET solutions, integrating gas analysis, spirometry, and ECG monitoring into comprehensive cardiopulmonary assessment platforms. In 2025, Vyaire’s CPET-related revenue is estimated at USD 0.06 Billion with a market share of approximately 17.50% , reflecting its status as one of the leading vendors in a Cardiopulmonary Exercise Test market projected by ReportMines to reach around USD 0.34 Billion in 2025.

   These figures indicate that Vyaire operates at a substantial scale relative to most niche competitors, benefiting from established distribution networks and long-standing relationships with hospital procurement teams. Its market share underscores strong competitiveness in high-acuity clinical environments, where reliability, service coverage, and compliance with cardiopulmonary testing standards are critical selection criteria. The company’s portfolio addresses both routine CPET for cardiac rehabilitation and advanced testing for complex cardiopulmonary disease, positioning it as a preferred vendor for tertiary care centers and integrated health systems.

   Vyaire’s strategic advantage stems from its deep expertise in respiratory care, validated calibration technologies, and tight integration between CPET equipment and broader lung function testing solutions. The company differentiates itself through scalable platforms that support modular upgrades, allowing health systems to expand from basic metabolic carts to full CPET laboratories without replacing core infrastructure. In comparison to peers, Vyaire emphasizes service contracts, uptime guarantees, and training programs for respiratory therapists and cardiologists, which strengthens customer retention and raises switching costs. This combination of clinical credibility, service intensity, and modular system design solidifies its competitive positioning as the CPET market grows at an estimated 6.90% CAGR through 2032.

2. MGC Diagnostics Corporation:

   MGC Diagnostics Corporation plays a critical role in the Cardiopulmonary Exercise Test market by focusing on advanced metabolic carts and integrated gas exchange analysis systems that are widely adopted in cardiology, pulmonology, and sports performance research. The company is recognized for high-fidelity breath-by-breath analysis, robust data acquisition, and sophisticated interpretation software tailored for CPET protocols such as VO2 max testing and ventilatory threshold determination. In 2025, MGC Diagnostics’ CPET-related revenue is estimated at USD 0.05 Billion with a market share of about 15.00% , placing it among the top-tier vendors in this specialized diagnostic segment.

   This revenue and share profile illustrates that MGC Diagnostics commands strong competitiveness, particularly in facilities that prioritize precision gas exchange measurements and detailed cardiopulmonary exercise interpretation. The company is especially relevant for academic medical centers, research institutions, and specialized cardiopulmonary clinics that require reproducible test results for both clinical decision-making and clinical trials. Its systems are widely perceived as research-grade platforms, which enhances brand prestige and helps influence equipment selection in teaching hospitals and performance laboratories.

   MGC Diagnostics differentiates itself primarily through its software analytics, flexible protocol configuration, and interoperability with hospital information systems and electronic health records. The company’s strategic capabilities include long-term experience in CPET-specific hardware design, calibration technologies that minimize drift during high-intensity protocols, and strong support for guideline-based reporting formats. Compared with diversified conglomerates, MGC Diagnostics is more narrowly focused on respiratory and exercise diagnostics, which allows it to innovate quickly in niche areas such as pediatric CPET, pre-operative risk stratification, and heart failure assessment. This focus-based strategy enables the company to defend its share in a market that is becoming more data-driven and outcome-oriented.

3. COSMED Srl:

   COSMED Srl holds a significant presence in the Cardiopulmonary Exercise Test landscape, particularly through its portable and laboratory-grade metabolic and CPET systems used in cardiology, sports science, and human performance optimization. The company is known for combining compact hardware with versatile CPET software, enabling testing in clinical environments, rehabilitation facilities, and field settings such as athletic centers. For 2025, COSMED’s CPET-linked revenue is estimated at USD 0.04 Billion and a market share near 12.00% , reflecting a strong foothold in both clinical and performance-oriented segments of a USD 0.34 Billion global market.

   These numbers suggest that COSMED competes effectively against larger multinational device makers by focusing on flexibility, portability, and user-friendly workflows. A meaningful part of its sales stems from sports medicine, cardiopulmonary rehabilitation, and occupational health, where testing environments are diverse and mobility of equipment is highly valued. This diversified customer base reduces dependence on large hospital tenders and supports resilience against procurement cycles in public health systems.

   COSMED’s strategic advantages lie in its expertise in mobile CPET platforms, battery-powered metabolic carts, and integrated spirometry solutions that can operate in constrained spaces. The company differentiates itself through compact form factors, wireless sensor integration, and the ability to capture high-quality gas exchange data outside traditional lab settings. Compared with some competitors that focus primarily on hospital CPET labs, COSMED is well positioned to capitalize on rising demand for exercise prescription, athlete screening, and cardiometabolic risk assessment in outpatient and performance contexts. This positioning aligns with the market’s steady 6.90% CAGR and the broader shift toward preventive cardiopulmonary care.

4. Schiller AG:

   Schiller AG is a well-established player in cardiology diagnostics and leverages this position to participate meaningfully in the Cardiopulmonary Exercise Test market through integrated ECG and CPET solutions. Its systems often combine bicycle or treadmill ergometry with multi-lead ECG monitoring and respiratory gas analysis, targeted at cardiology clinics, heart failure centers, and sports cardiology units. In 2025, Schiller’s CPET-derived revenue is estimated at USD 0.03 Billion with a market share around 9.50% , indicating a solid but not dominant presence relative to the leading specialized vendors.

   This revenue and market share profile reflects Schiller’s strategy of embedding CPET into a broader cardiology diagnostics portfolio instead of focusing exclusively on exercise testing. The company’s CPET systems are frequently chosen by facilities that already use Schiller ECG, defibrillation, or monitoring equipment, benefiting from purchasing synergies and streamlined training requirements. Its relevance is particularly strong in regional hospitals and private cardiology practices that seek an integrated, cost-effective solution rather than multiple standalone systems.

   Schiller’s competitive differentiation centers on its long track record in ECG technology, robust ergometer integration, and user interfaces optimized for cardiology workflows. The company leverages its expertise in stress testing and arrhythmia detection to enhance CPET risk stratification for patients with ischemic heart disease and heart failure. Compared with firms that emphasize metabolic cart sophistication, Schiller focuses on cardiac safety, standardized stress protocols, and clear ECG reporting, making it attractive for cardiologists who prioritize cardiovascular risk assessment as the primary objective of CPET. This cardiology-centric approach allows Schiller to carve out a defensible segment as the CPET market expands in line with increasing cardiovascular disease prevalence.

5. GE HealthCare Technologies Inc.:

   GE HealthCare Technologies Inc. participates in the Cardiopulmonary Exercise Test market as part of its broader cardiovascular diagnostics and monitoring portfolio, leveraging its global footprint, digital ecosystem, and installed base of stress testing and imaging systems. Although CPET is a smaller component of its total revenue mix, the company’s brand recognition and integration with ECG stress systems provide a strategic entry point into tertiary hospitals and academic institutions. In 2025, GE HealthCare’s CPET-specific revenue is estimated at USD 0.03 Billion with a market share of roughly 8.50% , placing it as a strong but not dominant competitor in a market still led by more specialized players.

   These figures highlight GE HealthCare’s role as a diversified technology vendor where CPET serves as an adjunct to broader cardiovascular assessment pathways, including echocardiography, nuclear cardiology, and advanced imaging. Hospitals that already rely on GE platforms for stress ECG and imaging often consider its CPET solutions to simplify vendor management, service contracts, and data integration. This cross-selling capability compensates for the company’s relatively narrower standalone CPET portfolio compared with niche vendors focused solely on exercise testing.

   GE HealthCare’s strategic advantages include robust connectivity to enterprise imaging archives, interoperable data flows into electronic health records, and advanced analytics capabilities across cardiology workflows. The company differentiates itself by positioning CPET within multimodality cardiac assessment strategies, enabling clinicians to correlate exercise capacity with imaging findings and hemodynamic parameters. Relative to competitors that concentrate on metabolic cart technology, GE emphasizes enterprise-level integration, cybersecurity, and scalable platforms for large health systems. This positioning makes it particularly relevant for organizations pursuing standardized cardiovascular care pathways across multiple sites.

6. Koninklijke Philips N.V.:

   Koninklijke Philips N.V. is a major multinational in health technology and contributes to the Cardiopulmonary Exercise Test market through integrated cardiology and respiratory monitoring solutions. The company’s CPET offerings are embedded within broader cardiology stress testing and patient monitoring ecosystems, enabling comprehensive assessment of exercise tolerance and cardiopulmonary response in hospital and outpatient settings. In 2025, Philips’ CPET-related revenue is estimated at USD 0.03 Billion with a market share near 8.00% , indicating a meaningful but not leading share within a competitive global market.

   This revenue and market share profile reflects Philips’ strategy of leveraging CPET as part of integrated care solutions, rather than as a standalone product line. The company utilizes its strength in patient monitoring, ECG, and connected care platforms to position CPET as one node in a continuous cardiac care continuum that spans diagnosis, treatment, and follow-up. Hospitals adopting Philips enterprise solutions can integrate CPET data into central monitoring stations and analytics dashboards, supporting longitudinal tracking of patients with heart failure, pulmonary hypertension, or post-surgical recovery.

   Philips differentiates itself through strong capabilities in connectivity, telehealth integration, and data visualization, which are increasingly important as health systems seek to manage chronic cardiopulmonary disease populations more efficiently. Its strategic advantages include user-friendly interfaces, cloud-enabled data management, and compatibility with hospital IT infrastructure. Compared with specialized CPET vendors that emphasize hardware innovation, Philips focuses on embedding CPET into value-based care models, leveraging remote monitoring and decision-support tools. This approach aligns with growing demand for integrated cardiopulmonary care pathways and positions Philips to capture incremental CPET growth as the market expands toward an estimated USD 0.54 Billion by 2032.

7. Cardioline S.p.A.:

   Cardioline S.p.A. is a focused cardiology diagnostics company that extends its portfolio into the Cardiopulmonary Exercise Test market through stress ECG and CPET solutions tailored for cardiology clinics and hospital departments. The company is particularly active in European markets, where it supplies ECG, holter, and stress testing systems, often bundling CPET capabilities with ergometry and ECG monitoring. For 2025, Cardioline’s CPET-specific revenue is estimated at USD 0.02 Billion with a market share of about 5.00% , reflecting a niche but growing role in this diagnostic segment.

   These figures show that Cardioline competes as a mid-sized player, leveraging cardiology specialization to gain share in certain regional markets and private practice networks. Its scale is smaller than that of global giants, but the company’s agility allows it to adapt product configurations and pricing to the needs of cardiology practices, diagnostic centers, and mid-sized hospitals. Its relevance is especially strong where buyers prioritize straightforward cardiology workflows, local language support, and responsive technical service over advanced research capabilities.

   Cardioline’s strategic advantage lies in its deep focus on cardiology and its ability to offer coherent product families spanning resting ECG, stress testing, and CPET. The company differentiates itself with streamlined user interfaces, compact workstation designs, and competitive pricing that appeals to smaller providers. In contrast to research-driven CPET vendors, Cardioline targets practical clinical applications, such as evaluating ischemia under load and assessing exercise capacity in cardiac rehabilitation. This positioning supports incremental CPET adoption in cardiology practices that may be transitioning from routine stress ECG to more comprehensive cardiopulmonary evaluation.

8. Nihon Kohden Corporation:

   Nihon Kohden Corporation is a major diagnostic and monitoring equipment supplier in Asia and globally, participating in the Cardiopulmonary Exercise Test market primarily through its cardiology and patient monitoring platforms. Its CPET-related solutions integrate ECG, hemodynamic monitoring, and exercise testing protocols, targeting hospitals and specialized cardiology centers that value reliability and strong service networks. In 2025, Nihon Kohden’s CPET-focused revenue is estimated at USD 0.02 Billion with a market share of approximately 4.50% , underscoring a solid but regionally skewed presence.

   These numbers suggest that Nihon Kohden has particular strength in Japan and selected Asia-Pacific markets, where its broader monitoring portfolio provides a strong base for CPET adoption. Hospitals often choose its CPET solutions to ensure compatibility with existing ECG and monitoring systems, benefiting from unified service contracts and consistent user interfaces across devices. While the company does not dominate the global CPET field, it maintains a competitive position in markets where brand familiarity and local support are decisive purchasing factors.

   Nihon Kohden’s strategic advantages include a reputation for durable hardware, excellent signal quality in ECG monitoring, and strong technical support infrastructure. The company differentiates itself by emphasizing reliability, patient safety, and compliance with regional regulatory requirements, which is particularly important in high-volume public hospitals. Compared to more research-oriented CPET vendors, Nihon Kohden focuses on robust, clinically oriented exercise testing solutions that fit seamlessly into existing cardiology workflows. This pragmatic orientation helps it capture incremental demand as CPET becomes more integrated into routine cardiovascular risk stratification in its core markets.

9. Geratherm Respiratory GmbH:

   Geratherm Respiratory GmbH is a specialized respiratory diagnostics company that plays a focused yet important role in the Cardiopulmonary Exercise Test market. Its portfolio includes spirometry, body plethysmography, and CPET systems designed for pulmonary clinics, rehabilitation centers, and hospital respiratory departments. In 2025, the company’s CPET-related revenue is estimated at USD 0.01 Billion with a market share near 3.50% , making it a smaller but technically competent player within the overall market.

   These figures indicate that Geratherm Respiratory operates primarily in niche respiratory care segments rather than pursuing broad cardiology adoption. Its CPET solutions are frequently selected by pulmonologists who require tight integration with lung function testing and prefer a unified vendor for respiratory diagnostics. This specialization allows the company to compete effectively in tenders that prioritize advanced pulmonary function features and accurate ventilatory response measurement during exercise.

   Geratherm Respiratory’s strategic advantages include deep domain expertise in respiratory diagnostics, high-quality flow and gas sensors, and software that correlates resting lung function with exercise performance. The company differentiates itself through comprehensive pulmonary-focused workflows, making CPET an extension of pulmonary function laboratories rather than a separate cardiology procedure. Relative to larger conglomerates, Geratherm can respond quickly to evolving pulmonary guidelines and niche requirements, such as CPET for pre-transplant evaluation or interstitial lung disease assessment. This focus supports steady participation in the CPET market as the prevalence of chronic respiratory diseases continues to drive demand for detailed functional testing.

10. Masterscreen GmbH:

    Masterscreen GmbH is closely associated with pulmonary function and CPET technologies that have been widely used in respiratory laboratories and academic centers. Within the Cardiopulmonary Exercise Test market, the company is recognized for modular systems that combine spirometry, diffusion capacity, and exercise testing into integrated diagnostic workstations. For 2025, Masterscreen’s CPET-derived revenue is estimated at USD 0.01 Billion with a market share of about 3.00% , reflecting its role as a specialized but smaller contributor to global CPET revenues.

    This revenue and market share pattern indicates that Masterscreen is particularly relevant in facilities that emphasize comprehensive pulmonary diagnostics and value modular system architecture. Its equipment is often found in university hospitals and specialized respiratory centers where clinicians use CPET to differentiate cardiac from pulmonary limitations and to evaluate complex dyspnea. While the company does not match the scale of the largest vendors, it maintains a loyal customer base that appreciates its focus on respiratory physiology.

    Masterscreen’s competitive differentiation is rooted in technical precision, flexible configuration options, and the seamless integration of resting and exercise-based pulmonary measurements. The company’s systems allow laboratories to build customized diagnostic suites, adding CPET capabilities when financial and clinical priorities align. Compared with larger multi-portfolio companies, Masterscreen can offer more tailored configurations and maintain close relationships with specialist users. This strategy positions it well in a segment of the CPET market where depth of respiratory analysis and configurability outweigh broad brand recognition.

11. CAE Healthcare:

    CAE Healthcare operates in the Cardiopulmonary Exercise Test market from an indirect but strategically relevant angle, leveraging its core strength in medical simulation and training. Rather than being a primary vendor of CPET hardware, CAE Healthcare contributes through simulation systems that incorporate cardiopulmonary physiology models and can be used to train clinicians in exercise testing protocols, interpretation, and emergency management during stress testing. In 2025, CAE Healthcare’s revenue associated with CPET-related solutions and simulation modules is estimated at USD 0.01 Billion with a market share around 2.50% when considering the broader ecosystem of CPET-enabling technologies.

    These figures demonstrate that CAE Healthcare’s direct share of CPET equipment revenue is limited, yet its influence on how clinicians learn and standardize CPET procedures is significant. Academic centers and teaching hospitals that deploy CAE simulators can train physicians, nurses, and technicians to manage cardiopulmonary stress scenarios, which indirectly supports safer and more effective real-world CPET deployment. This training capability can be particularly valuable in markets where CPET adoption is expanding and clinical teams require upskilling.

    CAE Healthcare’s strategic advantage stems from its sophisticated simulation platforms, realistic patient scenarios, and analytics that track learner performance. The company differentiates itself by enabling institutions to reduce training-related risks and improve protocol adherence before implementing high-stakes cardiopulmonary exercise tests on patients. Compared to hardware-focused CPET vendors, CAE Healthcare’s contribution lies in the human capital side of the market, helping to address workforce competency gaps that can otherwise constrain CPET utilization. This role becomes increasingly important as the global CPET market grows at an estimated 6.90% CAGR and more centers seek to incorporate exercise testing into clinical pathways.

12. Ergoline GmbH:

    Ergoline GmbH is a key supplier of ergometers and exercise testing equipment, making it an important enabler within the Cardiopulmonary Exercise Test value chain. Its bicycle and treadmill ergometers are frequently integrated into CPET systems from multiple diagnostic vendors, supporting standardized workload protocols for cardiology and pulmonary testing. In 2025, Ergoline’s revenue directly tied to CPET-related ergometry solutions is estimated at USD 0.01 Billion with a market share of roughly 3.00% when referencing the CPET equipment segment.

    These figures indicate that Ergoline plays a specialized but essential role, as reliable and accurate ergometers are critical for delivering reproducible CPET results. Many hospitals and diagnostic centers select CPET platforms partly based on the perceived quality and durability of the integrated ergometer, which elevates Ergoline’s importance within multi-vendor configurations. Its products are widely used in cardiac rehabilitation, sports cardiology, and research, providing standardized load increments and precise control of exercise protocols.

    Ergoline’s strategic advantage lies in its engineering expertise in medical-grade ergometry, long product lifecycles, and compatibility with CPET and ECG systems from various manufacturers. The company differentiates itself through robust mechanical design, patient safety features, and configurable interfaces that can be tailored to different clinical and research requirements. Unlike vendors that focus on gas analysis or software analytics, Ergoline concentrates on the exercise modality itself, ensuring smooth, controlled workloads that underlie high-quality CPET measurements. This focus allows it to partner with multiple CPET system providers and maintain relevance across geographies and care settings.

13. Medical Graphics Shanghai Ltd.:

    Medical Graphics Shanghai Ltd. serves as an important regional player in the Cardiopulmonary Exercise Test market, particularly within China and parts of Asia-Pacific. Leveraging technology heritage connected to established CPET brands, the company supplies metabolic carts and CPET systems adapted to local regulatory requirements, language needs, and pricing structures. In 2025, its CPET-related revenue is estimated at USD 0.01 Billion with a market share of about 3.00% , underscoring a growing but still regionally concentrated presence.

    These figures show that Medical Graphics Shanghai is not yet a global leader, but it occupies a strategically important position in a fast-growing healthcare market. Chinese hospitals and research institutes increasingly adopt CPET for evaluating heart failure, pulmonary disease, and athlete performance, and they often favor vendors that can provide localized service and support. The company benefits from proximity to customers, understanding of local procurement processes, and the ability to adjust configurations and pricing for different tiers of hospitals.

    Medical Graphics Shanghai’s strategic advantages include regional manufacturing or assembly capabilities, local language software, and service teams that can respond quickly to installation and maintenance needs. It differentiates itself by combining recognized CPET technology frameworks with localization, which can lower barriers to adoption in secondary and tertiary hospitals. Compared with global players that may have higher price points and longer response times, this localized approach helps the company gain share in tenders where cost-effectiveness and support responsiveness are critical criteria. As CPET adoption in China increases alongside rising cardiovascular and respiratory disease burdens, Medical Graphics Shanghai is positioned to grow its influence within the broader market.

14. NSpire Health Inc.:

    NSpire Health Inc. is a specialized respiratory diagnostics company that extends its capabilities into the Cardiopulmonary Exercise Test market through integrated pulmonary function and CPET systems. Its platforms are used in pulmonary laboratories, academic hospitals, and specialty clinics focused on asthma, COPD, and complex respiratory disorders. For 2025, NSpire Health’s CPET-related revenue is estimated at USD 0.02 Billion with a market share close to 5.50% , placing it among the notable mid-sized players in a market dominated by a handful of larger competitors.

    These figures suggest that NSpire Health has leveraged its strong position in pulmonary diagnostics to gain traction in CPET, particularly where clinicians require nuanced differentiation between cardiac and pulmonary limitations. Its solutions are often selected for advanced respiratory evaluation, including assessment of unexplained dyspnea and pre-operative risk stratification for thoracic surgery. The company’s presence is especially relevant in institutions where respiratory physiologists are key decision-makers for equipment procurement.

    NSpire Health’s strategic advantages include high-performance flow and gas analysis technologies, comprehensive pulmonary function testing portfolios, and software that integrates resting and exercise data into cohesive reports. The company differentiates itself by emphasizing respiratory pathophysiology and by offering CPET as a natural extension of pulmonary laboratories rather than a stand-alone cardiology tool. Compared to generalist vendors, NSpire can align product development closely with emerging respiratory guidelines and research, making it attractive for centers at the forefront of pulmonary care. This specialization positions the company well to capture additional share as CPET becomes more embedded in respiratory disease management strategies.

15. Cortex Biophysik GmbH:

    Cortex Biophysik GmbH is a highly specialized CPET and metabolic testing company with a strong reputation in sports science, performance diagnostics, and advanced cardiopulmonary research. Its systems are widely used in elite athlete performance centers, university laboratories, and specialized clinical facilities that demand high-precision breath-by-breath analysis and robust ergospirometry. In 2025, Cortex’s CPET-focused revenue is estimated at USD 0.02 Billion with a market share of roughly 6.50% , positioning it as a key specialist player in a market of USD 0.34 Billion.

    These numbers highlight Cortex’s competitive strength in segments where measurement accuracy, protocol flexibility, and advanced analytics are more important than broad hospital integration. A significant portion of its revenue comes from sports and exercise science applications, including VO2 max testing, lactate threshold determination, and individualized training prescription. In clinical contexts, its systems support high-level CPET for heart failure assessment, pulmonary hypertension evaluation, and pre-operative risk stratification, particularly in centers that engage heavily in research.

    Cortex’s strategic advantages include cutting-edge sensor technology, robust validation in performance settings, and highly configurable software capable of handling complex testing protocols. The company differentiates itself by offering portable and laboratory-grade ergospirometry devices that can be used in field environments as well as controlled labs, appealing to both sports and clinical customers. Compared with larger multi-product vendors, Cortex maintains a sharp focus on CPET and related performance diagnostics, allowing rapid innovation cycles and close collaboration with research partners. This focus positions Cortex to benefit from growing demand at the intersection of sports performance, preventive cardiology, and metabolic health, supporting sustained participation in a market projected to grow at a 6.90% CAGR through 2032.